Gilead Sciences, Inc. (GILD - Analyst Report) made a strong start to 2014, with both revenues as well as earnings beating expectations by huge margins in the first quarter of the year. The company’s first-quarter 2014 earnings (including stock-based compensation expenses but excluding other special items) of $1.44 per share blew past the Zacks Consensus Estimate of 75 cents per share. Moreover, first quarter 2014 earnings were way above the year-ago figure of 45 cents per share. We expect the stellar first quarter 2014 results to have a significant positive impact on the company’s stock price.
Read the Full Research Report on ALXNRead the Full Research Report on REGNRead the Full Research Report on GILDRead the Full Research Report on CELGZacks Investment Research
The massive growth in earnings was attributable to the exceptional performance of Gilead’s newly approved hepatitis C virus (HCV) drug Sovaldi in its first full quarter in the market.
Sovaldi’s strong sales helped Gilead record total revenues of $5 billion, way above the year-ago figure of $2.53 billion. Quarterly revenues easily surpassed the Zacks Consensus Estimate of $4 billion.
Including one-time items, the biopharmaceutical company reported first quarter earnings of $1.33 per share, well above the year-ago earnings of 43 cents.
The First Quarter in Details
With Sovaldi registering sales in excess of $2 billion ($2.27 billion to be exact) in its first full quarter in the market, it was not surprising that product sales more than doubled (103.8% growth) to $4.87 billion. Though Sovaldi sales grabbed the headlines, some other anti-viral products, such as HIV treatments Complera/Eviplera (up 69% to $250.7 million) and Stribild (launched in the U.S. and the EU in Aug 2012 and May 2013 respectively) performed very well. Stribild sales came in at $215.3 million, up 5.7% sequentially. Sales of older HIV drugs like Truvada, Viread and Atripla were mixed. Truvada sales increased 8% to $759.7 million, Viread sales were flat at $210.6 million but Atripla sales declined 11% to $779.6 million.
The exceptionally strong performance by Sovaldi led to antiviral product sales for the quarter registering a massive growth of 119% to $4.51 billion. The U.S. market was the chief beneficiary of Sovaldi’s strong sales. The HCV treatment registered sales of $2.1 billion in the U.S., where it was approved in Dec 2013. Consequently, the U.S. market was the major contributor ($3.36 billion, up 190.5%) to antiviral product sales. Europe contributed $949.4 million (up 26.5%) to antiviral product sales. EU approval for Sovaldi was gained in Jan 2014 and the drug registered European sales of $163.7 million in the reported quarter. Other products including Letairis, Ranexa and AmBisome recorded sales of $122.9 million (up 4%), $111.6 million (up 16%) and $92.1 million (up 8%), respectively. Gilead’s royalty, contract and other revenues fell marginally to $76.6 million.
On the operational front (including stock-based compensation expenses but excluding other special items), operating margin improved to 65.0% from 42.1% a year ago. Research & development (R&D) expenses climbed 21.6% to $592.2 million in the first quarter of 2014 while selling, general and administrative (SG&A) expenses surged approximately 49% to $545.3 million. The rise in R&D expenses was primarily driven by Gilead’s efforts to develop its HIV and oncology pipeline. The increase in SG&A expenses was primarily attributable to Gilead’s efforts to expand. Costs associated with the ongoing launches of Sovaldi in the U.S. and the anticipated launch of oncology candidate idelalisib also pushed up SG&A expenses.
2014 View Maintained
Gilead maintained its guidance for 2014 which was originally provided by the company in Feb 2014 while releasing its fourth quarter and full year 2013 results.
Gilead still expects product sales in the range of $11.3–$11.5 billion, well above the $10.8 billion recorded in 2013. However, we expect Gilead to record much higher product sales in 2014 as the company’s guidance excludes Sovaldi sales. The company’s decision not to provide guidance for 2014 Sovaldi sales can be viewed as the only disappointing aspect of the earnings report and may dampen investor enthusiasm to some extent.
Adjusted product gross margin for 2014 is still projected in the range of 75%–77%. Adjusted effective tax rate continues to be projected in the range of $28%–$29%. The company maintained that adjusted gross margin will improve by 0.75%–1% and adjusted effective tax rate will decline by the same amount for every $1 billion Sovaldi sales.
R&D expenses (excluding stock based compensation expenses and other special items) are projected in the range of $2.2–$2.3 billion, well over 2013 levels. SG&A expenses are still forecasted in the range of $2.1–$2.2 billion, well above the 2013 figure.
We are very impressed by Sovaldi’s stellar performance in the first quarter of 2014. We expect Sovaldi sales to continue growing throughout 2014. The blockbuster product should see strong demand until an improved treatment enters the market. The product’s outstanding performance in the quarter should go a long way in justifying its high price tag. The drug costs $84,000 for a 12-week treatment period in the U.S. We remind investors that Sovaldi’s high price had invited criticisms from various quarters. The drug’s outstanding performance should lay to rest such concerns. Other products such as Complera/Eviplera and Stribild also should continue performing well.
Focus will also be on Gilead’s pipeline. Idelalisib is one of the most interesting candidates at Gilead. The candidate is under review in the U.S. for the chronic lymphocytic leukemia (action date: Aug 6, 2014) and indolent non-Hodgkin’s lymphoma indications (target date: Sep 11, 2014).
After Sovaldi, Gilead is looking to get its next HCV treatment, a fixed dose combination of ledipasvir and Sovaldi, approved in the U.S. The U.S. Food and Drug Administration (FDA) will decide on the approval status of this cocktail treatment by Oct 10. The month of October is likely to see a couple of more FDA decisions on Gilead’s candidates. While the U.S. regulatory body will decide on cobicistat’s regulatory status by Oct 3, it will decide on elvitegravir by Oct 4.
Other major biopharma players reporting this week include Celgene Corporation (CELG - Analyst Report) and Alexion Pharmaceuticals (ALXN - Analyst Report) .
Gilead carries a Zacks Rank #2 (Buy). A better-ranked stock in the biopharma space is Regeneron Pharmaceuticals (REGN - Analyst Report) carrying a Zacks Rank #1 (Strong Buy).